Navigation Links
Innovive Pharmaceuticals Announces Preclinical Data from INNO-206,Oncology Program

NEW YORK--(BUSINESS WIRE)--Apr 18, 2007 - INNOVIVE Pharmaceuticals, Inc. (OTCBB:IVPH) announced data from preclinical evaluation of the company's drug candidate INNO-206, a doxorubicin prodrug for treatment of a variety of tumor types. Researchers found that INNO-206, a form of doxorubicin that attaches to circulating albumin and becomes activated once located at the tumor site, is much better tolerated in animal models than doxorubicin alone, a commonly prescribed chemotherapeutic agent. Data was presented today at the American Association for Cancer Research 2007 Annual Meeting in Los Angles, CA.

In a poster presentation titled "Reduced chronic cardiotoxicity and mitochondrial damage of the (6-maleimidocaproyl) hydrazone derivative of doxorubicin (DOXO-EMCH) in a rat model compared to doxorubicin" (Abstract # 5587), researchers concluded:

-- INNO-206 has the potential of inducing less acute and chronic cardiotoxicity in humans compared to doxorubicin

-- INNO-206 low-dose and high-dose groups did not differ from controls with regard to clinical symptomatology and mortality, whereas animal subjects exposed to doxorubicin had a severe clinical and histopathogical cardiomyopathy, marked by enlarged heart with inefficient pumping of blood

-- INNO-206 low-dose and high-dose groups showed a slight increase in heart weights compared to control animals, in contrast to significant increase in heart weight following treatment with doxorubicin

-- INNO-206 low-dose and high-dose groups respectively had low cardiomyopathy scores of one and three on average, in contrast to the doxorubicin group having a high cardiomyopathy score of seven

These data suggest that the proposed Phase II dose of 200 mg/m2 should demonstrate mild to no cardiotoxicity in patients. Innovive intends to initiate a Phase II study in Small Cell Lung Cancer in Q207.

About INNO-206

INNO-206 (formerly DOXO-
'"/>




Page: 1 2 3

Related medicine technology :

1. Innovive Pharmaceuticals to Present Interim Data from Phase I Study of INNO-406 at the American Society of Clinical Oncology Annual Meeting
2. Innovive Pharmaceuticals Announces Additional Data Presentations at American Association for Cancer Research Annual Meeting
3. Innovive Pharmaceuticals Announces Data from Oncology Drug Programs to be Presented at American Association for Cancer Research Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:8/27/2014)... Aug. 28, 2014 China Nepstar Chain ... the "Company"), a leading retail drugstore chain in ... stores, today announced its unaudited financial results for ... Financial HighlightsFor the quarter ended June 30, 2014: ... million) compared to RMB638.8 million in the second ...
(Date:8/27/2014)... , Aug. 27, 2014 TWi Pharmaceuticals, ... approval from the United States Food and Drug ... (ANDA) for megestrol acetate 125mg/ml oral suspension, the ... is the first-to-file and under Hatch Waxman rules, ... marketing exclusivity.  TWi has completed the pre-launch preparation ...
(Date:8/27/2014)... 27, 2014 Reportbuyer.com has added ... Collaborative R&D Terms & Agreements in Pharma, ... The Collaborative R&D Terms and ... provides comprehensive understanding and unprecedented access to ... into by the worlds leading life science ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 11TWi Pharmaceuticals Receives US FDA Final Approval on Generic Megestrol Acetate 125mg/ml Oral Suspension 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 4Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 5Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 6Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 7Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 8Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 9
... Mylan Inc. (Nasdaq: MYL ) today ... final approval from the U.S. Food and Drug Administration ... Ibandronate Sodium Tablets, 150mg. This product is the generic ... treatment and prevention of osteoporosis in postmenopausal women. ...
... YORK, March 20, 2012 Reportlinker.com ... report is available in its catalogue: ... Market: Western Europe Market Size, Segment ... http://www.reportlinker.com/p0797078/Nutraceuticals-Product-Market-Western-Europe-Market-Size-Segment-And-Country-Analysis-And-Forecasts-2007-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Nutraceutical ...
Cached Medicine Technology:Nutraceuticals Product Market: Western Europe Market Size, Segment And Country Analysis And Forecasts (2007-2017) 2Nutraceuticals Product Market: Western Europe Market Size, Segment And Country Analysis And Forecasts (2007-2017) 3Nutraceuticals Product Market: Western Europe Market Size, Segment And Country Analysis And Forecasts (2007-2017) 4
(Date:8/28/2014)... 2014 Alpine, NJ resident Othon Mourkakos ... team, Zebras In Tiaras, to benefit the Immune Deficiency ... October 26, 2014 in Foley Square, New York. ... Primary immunodeficiency diseases (PI) are a group of more ... of the body’s immune system is missing or functions ...
(Date:8/28/2014)... CA (PRWEB) August 28, 2014 MarijuanaDoctors.com ... California physician, James Patel M.D. of Livermore, California. As ... best and most qualified physicians, and in accordance with ... our patients to Dr. Patel’s practice. , Initially finding ... a young age, Dr. Patel was shaped by his ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 MMAR Medical ... program is a chance for regular customers to enjoy ... without the need for a wholesale license. It’s a ... semi-professional athletic programs and others who regularly purchase medical ... , “Whether supporting your own active lifestyle or those ...
(Date:8/28/2014)... 28, 2014 The Pulmonica is a ... resonant, meditative sounds that can be felt vibrating in ... to use it – just taking long, slow, deep ... , Here are some examples of how to ... your eyes, relax, and maintain good posture. Try to ...
(Date:8/28/2014)... 28, 2014 Coveros, Inc., the ... that it has partnered with InfoZen on the ... start date of 2/4/2014 with U.S. Citizenship and ... (DHS) agency that oversees lawful immigration to the ... InfoZen will automate the integration and delivery of ...
Breaking Medicine News(10 mins):Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 2Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 3Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 4Health News:MMAR Medical Announces Customer Membership Program 2Health News:Ever Thought of Meditating With a Harmonica; Harmonica Techs, Inventors of the Pulmonica® Pulmonary Harmonica®, Present Tips on How to Relax with Soothing Sounds 2Health News:Coveros Partners with InfoZen on USCIS Transformation Integration Award 2
... 1, 2011) Two new studies published in the ... (JNM) provide insight into the potential of positron ... and to identify pharmaceuticals to slow the progress of ... the Alzheimer,s Association guidelines for detecting Alzheimer,s-related brain changes ...
... , MONDAY, Aug. 1 (HealthDay News) -- Despite the ... -- which can be done at home or in day ... However, colon cleansing can cause serious side effects ranging ... the report say. Colon cleansing -- also called colonic ...
... breast cancer patients who don,t respond to tamoxifen ... from the Kimmel Cancer Center at Jefferson ... combined with dasatinib, a protein-tyrosine kinase inhibitor, reverses ... surrounding tissue by normalizing glucose intake and reducing ...
... , SUNDAY, July 31 (HealthDay News) -- A ... been pinpointed by a team of researchers working together ... The PYHIN1 gene variant was not present in ... gene variant to be identified in black Americans. ...
... obesity are heavily rooted in the notion of personal ... healthy foods and portion sizes consistent with weight loss ... According to preventive medicine and behavioral experts at Rush ... that views obesity as a result of neurobehavioral processes ...
... By Amanda Gardner HealthDay Reporter , FRIDAY, ... Drug Administration should scrap the system it uses to ... joints and heart pacemakers, according to a highly anticipated ... come up with a legally sound process that ensures ...
Cached Medicine News:Health News:New JNM research supports upcoming Alzheimer's disease guidelines 2Health News:Colon Cleansing Has No Health Benefit, May Harm: Report 2Health News:Leukemia drug reverses tamoxifen-resistance in breast cancer cells 2Health News:Obesity counseling should focus on neurobehavioral processes, not personal choice, researchers say 2Health News:Obesity counseling should focus on neurobehavioral processes, not personal choice, researchers say 3Health News:Report Urges New Review System for Medical Devices 2Health News:Report Urges New Review System for Medical Devices 3
Full Handle Laseredge Implant Blade Knife, 5.2 mm angled bevel up. Blade dimension: 16.5 mm x 5.2 mm x 4.2 mm x 1.6 mm....
Full Handle Laseredge Crescent Blade Knife, angled double bevel. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Stab Blade Knife, 22.5 blade. Blade tip dimension: 10.7 mm x 1.8 mm x 4.2 mm....
18 gauge straight. Fine tip. Lightweight design offers precise hemostasis. Pencil design minimizes tissue trauma and induced astigmatism. Knurled handle provides a sure grip and better manipulation....
Medicine Products: